{"filing":{"accession_number":"0001193125-26-397221","cik":"0001907108","ticker":"LXEO","company_name":"Lexeo Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-16","primary_document":"lxeo-20260916.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-20260916.htm"},"events":[{"id":34169,"run_id":31439,"accession_number":"0001193125-26-397221","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"Lexeo Therapeutics entered into a definitive Agreement and Plan of Merger on September 16, 2026, to acquire Mantle Therapeutics Inc. for $8.3 million in upfront consideration (cash and equity) plus up to $13.0 million in contingent milestone payments, totaling up to $21.3 million. The acquisition brings four therapeutic candidates (LX3010, LX3030, LX3050, LX3070) designed to address Friedreich ataxia, materially expanding Lexeo's platform and pipeline.","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37832,"accession_number":"0001193125-26-397221","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Lexeo entered into a definitive Agreement and Plan of Merger on September 16, 2026, to acquire Mantle Therapeutics Inc. for $8.3 million in upfront consideration (cash and equity) plus up to $13.0 million in contingent milestone payments. The transaction involves a material acquisition of a clinical-stage company with multiple therapeutic candidates (LX3010, LX3030, LX3050, LX3070) designed to address Friedreich ataxia, expanding Lexeo's platform beyond its existing gene therapy focus. This is a classic Item 1.01 material acquisition disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:44.442196+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37833,"accession_number":"0001193125-26-397221","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure centers on Lexeo's entry into a definitive merger agreement to acquire Mantle Therapeutics Inc. for $8.3 million upfront plus up to $13.0 million in milestone payments (total $21.3 million). The press release explicitly states \"Lexeo entered into an agreement to acquire Mantle Therapeutics Inc.\" and describes the acquired portfolio of four therapeutic programs (LX3010, LX3030, LX3050, LX3070) designed to expand Lexeo's Friedreich ataxia platform. This is a material acquisition that would significantly affect investor assessment of the company's strategic direction and pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:44.442196+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37832,"accession_number":"0001193125-26-397221","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Lexeo entered into a definitive Agreement and Plan of Merger on September 16, 2026, to acquire Mantle Therapeutics Inc. for $8.3 million in upfront consideration (cash and equity) plus up to $13.0 million in contingent milestone payments. The transaction involves a material acquisition of a clinical-stage company with multiple therapeutic candidates (LX3010, LX3030, LX3050, LX3070) designed to address Friedreich ataxia, expanding Lexeo's platform beyond its existing gene therapy focus. This is a classic Item 1.01 material acquisition disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:44.442196+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-09-22"},{"id":37833,"accession_number":"0001193125-26-397221","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure centers on Lexeo's entry into a definitive merger agreement to acquire Mantle Therapeutics Inc. for $8.3 million upfront plus up to $13.0 million in milestone payments (total $21.3 million). The press release explicitly states \"Lexeo entered into an agreement to acquire Mantle Therapeutics Inc.\" and describes the acquired portfolio of four therapeutic programs (LX3010, LX3030, LX3050, LX3070) designed to expand Lexeo's Friedreich ataxia platform. This is a material acquisition that would significantly affect investor assessment of the company's strategic direction and pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T11:09:44.442196+00:00","company_name":"Lexeo Therapeutics, Inc.","ticker":"LXEO","filing_date":"2026-09-22"}]}